Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is being developed for Rett syndrome, and the company’s pipeline is centered on CNS gene therapy candidates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaTSHA-102 and related clinical development activities for Rett syndrome.
Additional AAV-based CNS gene therapy candidates in preclinical or early development.
CMC, scale-up, and cGMP manufacturing support for clinical and future commercial supply.
Asiakkaat
Taysha does not sell approved products today; its direct counterparties are primarily regulators, clinical trial sites, contract manufacturers, and research collaborators that enable development. If approved, its eventual customers would be patients with severe CNS genetic diseases, with treatment access likely mediated by specialty healthcare providers and payers.
Females with Rett syndrome enrolled in REVEAL Phase 1/2 studies to evaluate TSHA-102.
Hospitals and research centers that administer study drug and collect safety/efficacy data.
CMOs that produce cGMP gene therapy material for clinical trials and future supply.
Academic and institutional partners that provide technology, know-how, or licensed IP.
Specialty neurology providers and reimbursement decision-makers for any approved therapy.
Strategia
Taysha’s strategy is to advance TSHA-102 through clinical development and regulatory review while building the manufacturing and quality capabilities needed for potential commercialization. It also seeks to broaden its CNS gene therapy pipeline through development, in-licensing, or acquisition of additional product candidates and technologies.
The company is highly dependent on its lead clinical program for value creation.
Later-stage development and BLA preparation require capabilities the company has not yet fully executed at scale.
Gene therapy programs require specialized CMC, supply chain, and launch infrastructure before approval.
A broader portfolio can reduce single-asset dependence and create additional development optionality.
Maantiede
The company is headquartered in the United States and conducts its development, regulatory, and financing activities from there. Its lead program is being advanced through U.S.-based FDA interactions and clinical trials, while future commercialization would depend on approvals in the U.S. and potentially other jurisdictions.
Riskit
Taysha is exposed to the high failure rate of clinical-stage biotechnology, where early signals may not translate into pivotal trial success or regulatory approval. The company is also concentrated in a single lead asset, so setbacks in TSHA-102, manufacturing, or regulatory review could materially affect its prospects.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
TSHA-102 must show durable safety and efficacy in later-stage studies to support approval.
Kohdistuu: Lead program TSHA-102
- Single-asset concentrationVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company is substantially dependent on one clinical candidate for value creation.
Kohdistuu: TSHA-102
- Regulatory delay or rejectionVaikutus: KorkeaTodennäköisyys: Korkea
The company has limited experience with pivotal trials and BLA submissions, increasing execution risk.
Kohdistuu: FDA and foreign regulatory pathways
- Manufacturing and CMC executionVaikutus: Korkea
AAV gene therapies require specialized process development, scale-up, and quality control.
Kohdistuu: cGMP supply and future commercial manufacturing
- Financing and dilution riskVaikutus: Korkea
As a pre-revenue biotech, continued development depends on external capital and access to markets.
Kohdistuu: Operating runway and future funding needs
Kirjanpito
Harkinnanvaraiset erätClinical, manufacturing, and regulatory costs flow through R&D and can vary sharply by trial activity.
Vaikutus: Affects operating loss and cash burn
Equity awards are a recurring non-cash cost for a development-stage biotech.
Vaikutus: Affects reported operating expenses and net loss
Manufacturing or lab-related assets may be written down if plans change or utilization falls.
Vaikutus: Can create non-cash charges in operating results
Collaboration or upfront payments, if any, may be recognized over time rather than immediately.
Vaikutus: Can affect revenue timing and operating cash flow
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Tenaya Therapeutics, Inc.
TNYA · Biological Products, (No Diagnostic Substances)
Tenaya Therapeutics is a U.S.-based clinical-stage biotechnology company focused on discovering and developing therapies for heart disease.
Anavex Life Sciences Corp
AVXL · Biological Products, (No Diagnostic Substances)
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Päivitetty: 24.9.2026